eftilagimod alpha
immutep
['eftilagimod', 'pdl']
#asco22 dr. presents phase ii study of 1l eftilagimod alpha (soluble lag-3 protein) + pembro in pdl1 unselected population. efti (subcutaneous) activates apcs and leads to more activated t cells with synergy with pd-1 inhibition. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him